 Sub-analyses of recently published work showed clinically relevant advantages of Envarsus versus twice-daily tacrolimus for prevention of treatment failure after 2-years among patients aged 65 and over age 65 yrs; -25.89 -45.11, 0.36, p0.067 Rostaing et al, AJKD 2016; Budde et al, AJT 2014. However, small numbers render the effect of borderline statistical significance 